Aytu BioPharma
AYTU
Aytu BioPharma (AYTU) earnings history
Most recent quarter
- Fiscal period
- Q3 2026
- Period end
- Mar 31, 2026
- EPS actual
- −$0.53
- EPS estimate
- −$0.44
- EPS surprise
- −19.56%
- Revenue surprise
- +2.97%
- Revenue
- $12.4M
- Revenue estimate
- $12.1M
- Reported
- May 13, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q3 2026 | May 13, 2026 | −$0.44 | −$0.53 | −19.56% | $12.4M | SEC |
| Q2 2026 | Feb 3, 2026 | −$0.41 | −$1.05 | −158.18% | $15.2M | SEC |
| Q1 2026 | Nov 13, 2025 | −$0.19 | −$0.08 | +57.89% | $13.9M | SEC |
| Q4 2025 | Sep 23, 2025 | −$0.03 | −$2.93 | −8698.80% | $15.1M | SEC |
| Q3 2025 | May 14, 2025 | −$0.17 | $0.20 | +217.65% | $18.5M | SEC |
| Q2 2025 | Feb 12, 2025 | −$0.28 | −$0.28 | +0.00% | $16.2M | SEC |
| Q1 2025 | Nov 13, 2024 | −$0.34 | −$0.20 | +41.18% | $16.6M | SEC |
| Q4 2024 | Sep 26, 2024 | −$0.45 | −$0.82 | −82.22% | $18.0M | SEC |
| Q3 2024 | May 15, 2024 | −$0.64 | −$0.52 | +18.75% | $18.0M | SEC |
| Q2 2024 | Feb 14, 2024 | −$0.25 | −$0.04 | +84.00% | $22.9M | SEC |
| Q1 2024 | Nov 14, 2023 | −$0.04 | −$1.48 | −3600.00% | $22.1M | SEC |
| Q4 2023 | Sep 27, 2023 | −$0.95 | −$0.59 | +37.89% | $30.7M | SEC |
| Q3 2023 | May 11, 2023 | −$0.63 | −$1.93 | −206.35% | $22.7M | SEC |
| Q2 2023 | Feb 21, 2023 | −$0.70 | −$2.15 | −207.14% | $26.3M | SEC |
| Q1 2023 | Nov 14, 2022 | −$3.60 | −$1.20 | +66.67% | $27.7M | SEC |
| Q4 2022 | Sep 27, 2022 | −$4.80 | −$9.80 | −104.17% | $27.4M | SEC |
| Q3 2022 | May 16, 2022 | −$22.00 | −$35.80 | −62.73% | $24.2M | SEC |
| Q2 2022 | Feb 14, 2022 | −$8.80 | −$8.80 | +0.00% | $23.1M | SEC |
| Q1 2022 | Nov 15, 2021 | −$9.80 | −$21.80 | −122.45% | $21.9M | SEC |
| Q4 2021 | Sep 27, 2021 | −$8.20 | −$16.20 | −97.56% | $23.5M | SEC |
Quarterly revenue
Frequently asked questions
When did Aytu BioPharma (AYTU) last report earnings?
Aytu BioPharma last reported on May 13, 2026, covering fiscal Q3 2026.
Did AYTU beat earnings estimates?
No. Aytu BioPharma reported EPS of −$0.53 for Q3 2026 against a −$0.44 estimate — a 19.56% miss.
How much revenue did AYTU report last quarter?
Aytu BioPharma reported $12.4M in revenue for Q3 2026, against a consensus estimate of $12.1M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.